Bruker reports Q2 EPS 50c, consensus 48c

Reports Q2 revenue $681.9M, consensus $647.86M. Frank Laukien, Bruker’s president and CEO, commented: “Bruker had a strong first half of the year, with organic revenue growth of 15.6% and non-GAAP EPS growth of 22.3% year-over-year. Our strong momentum supports the planned investments in our transformational Project Accelerate 2.0 initiatives, particularly in proteomics and spatial biology. In addition, we are investing in our recent acquisitions in proteomics consumables and proteomics drug discovery services, as well as in neuroscience research tools, applied market solutions and scientific software. Given our good first half results, solid bookings and backlog, we expect mid-to-high single digit organic revenue growth in the second half of 2023, and we are raising our organic revenue growth guidance for FY 2023 again.”